Article Text
Abstract
INTRODUCTION
Antibodies to the muscle acetylcholine receptor (AChR) are present in about 85% of patients with generalized myasthenia gravis, and 50% of patients with just ocular symptoms. However, up to 70% of the myasthenia patients without AChR antbodies, so called ‘seronegative’ myasthenia gravis, have antibodies to the muscle specific tyrosine kinase (MuSK). MuSK is another protein at the postsynaptic membrane of the neuromuscular junction, and plays a role in agrin-induced AChR clustering (Hoch et al. 2001). These patients may be difficult to recognize, and difficult to treat effectively. Here we describe four AChR antibody-negative/MuSK antibody-positive patients as examples.
THE CASES (SEE TABLE 1)
Case 1
This patient had an age at onset and clinical presentation typical of myasthenia gravis but was difficult to treat. She was a 30-year old woman who developed diplopia, dysphagia and dysarthria during the third trimester of her first pregnancy. EMG showed a defect of neuromuscular
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- Myasthenia gravis and other neuromuscular junction disorders
- New and emerging treatments for myasthenia gravis
- Persistent type 2 respiratory failure on background of advanced thymoma with lung metastases
- The use of rituximab in myasthenia gravis and Lambert–Eaton myasthenic syndrome
- Update on myasthenia gravis
- Myasthenia gravis presenting as bilateral pseudointernuclear ophthalmoplegia in a patient with an incidental prolactinoma
- The features of myasthenia gravis with autoantibodies to MuSK
- Myasthenia gravis
- Difference in distribution of muscle weakness between myasthenia gravis and the Lambert–Eaton myasthenic syndrome
- Extraocular muscle responses to high dose intravenous methylprednisolone in myasthenia gravis